Single-institution experience with gemcitabine-cisplatin combination therapy as a second-line treatment for patients with unresectable biliary tract cancer after failure of gemcitabine-S-1 combination therapy: a prospective feasibility study.
Ryusei MatsuyamaDaisuke MoriokaRyutaro MoriSeigo HirataniYasuhiro YabushitaYohei OtaTakafumi KumamotoKoichi TaniguchiItaru EndoPublished in: Cancer chemotherapy and pharmacology (2018)
Although some issues remain to be clarified, mainly due to the small sample size, this single-institution experience with GC as second-line treatment after failure of GS showed acceptable outcomes and good tolerability.